UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer

Molecules (Basel, Switzerland), 2018-08, Vol.23 (9), p.2191

2018

Volltextzugriff (PDF)

HDACs and HDAC inhibitors in colon cancer

Epigenetics, 2008-01, Vol.3 (1), p.28-37

Mariadason, John M.

2008

Volltextzugriff (PDF)

FunRich: An open access standalone functional enrichment and interaction network analysis tool

Proteomics (Weinheim), 2015-08, Vol.15 (15), p.2597-2601

2015

Volltextzugriff (PDF)

Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer

Cancer research (Chicago, Ill.), 2014-06, Vol.74 (12), p.3238-3247

2014

Volltextzugriff (PDF)

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells

PloS one, 2014-03, Vol.9 (3), p.e88950-e88950

2014

Volltextzugriff (PDF)

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles

Pharmaceutics, 2018-12, Vol.10 (4), p.283

2018

Volltextzugriff (PDF)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Cell death & disease, 2019-04, Vol.10 (5), p.342-342, Article 342

2019

Volltextzugriff (PDF)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

BMC cancer, 2022-05, Vol.22 (1), p.478-478, Article 478

2022

Volltextzugriff (PDF)

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

The Journal of biological chemistry, 2006-05, Vol.281 (19), p.13548-13558

2006

Volltextzugriff (PDF)

Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity

Nature communications, 2019-11, Vol.10 (1), p.5291-14, Article 5291

2019

Volltextzugriff (PDF)

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

Cancer research (Chicago, Ill.), 2008-03, Vol.68 (6), p.1953-1961

2008

Volltextzugriff (PDF)

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1217-1226

2016

Volltextzugriff (PDF)

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Clinical cancer research, 2021-04, Vol.27 (8), p.2159-2167

2021

Volltextzugriff (PDF)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Molecular cancer, 2017-06, Vol.16 (1), p.112-112, Article 112

2017

Volltextzugriff (PDF)

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Cancer research (Chicago, Ill.), 2010-07, Vol.70 (14), p.5901-5911

2010

Volltextzugriff (PDF)

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells

Antioxidants & redox signaling, 2015-07, Vol.23 (1), p.66-84

2015

Volltextzugriff (PDF)

SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer

Cancer research (Chicago, Ill.), 2013-01, Vol.73 (2), p.725-735

2013

Volltextzugriff (PDF)

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Clinical cancer research, 2013-02, Vol.19 (3), p.657-667

2013

Volltextzugriff (PDF)

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

Clinical cancer research, 2017-09, Vol.23 (18), p.5573-5584

2017

Volltextzugriff (PDF)

Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?

Trends in Cancer, 2017-10, Vol.3 (10), p.698-712

2017

Volltextzugriff (PDF)

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Biomedicines, 2024-05, Vol.12 (5), p.1117

2024

Volltextzugriff (PDF)

Molecular regulators of lipid metabolism in the intestine – Underestimated therapeutic targets for obesity?

Biochemical pharmacology, 2020-08, Vol.178, p.114091-114091, Article 114091

2020

Volltextzugriff (PDF)

Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

Scientific reports, 2023-02, Vol.13 (1), p.2422-2422, Article 2422

2023

Volltextzugriff (PDF)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Scientific reports, 2022-01, Vol.12 (1), p.1238-1238, Article 1238

2022

Volltextzugriff (PDF)

Intestinal-specific Hdac3 deletion increases susceptibility to colitis and small intestinal tumor development in mice fed a high-fat diet

American journal of physiology: Gastrointestinal and liver physiology, 2023-12, Vol.325 (6), p.G508-G517

2023

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(184)

Publikationsform

Artikel
(198)

Sprache

Englisch
(198)
Japanisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer

HDACs and HDAC inhibitors in colon cancer

FunRich: An open access standalone functional enrichment and interaction network analysis tool

Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer

Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer

Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity

PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells

SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Molecular regulators of lipid metabolism in the intestine – Underestimated therapeutic targets for obesity?

Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Intestinal-specific Hdac3 deletion increases susceptibility to colitis and small intestinal tumor development in mice fed a high-fat diet

Suchergebnisse filtern